Thomas O'Donnell, MD
Otolaryngology · Islandia, NYNPI 1821069469
Payments from drug & device makers
Across 117 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$525
- GSK$394
- Sanofi$272
- Aerin Medical Inc.$189
- Alk-abello, Inc$105
- Optinose US, Inc.$99
- plus $814 from 18 others
What the payments were for
- Consulting fees$231%
- Food & beverage$2,27795%
- Education$984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 26 | $525 |
| GSK | 19 | $394 |
| Sanofi | 15 | $272 |
| Aerin Medical Inc. | 6 | $189 |
| Alk-abello, Inc | 7 | $105 |
| Optinose US, Inc. | 5 | $99 |
| Arrinex, Inc. | 1 | $98 |
| Amgen | 5 | $91 |
| Medtronic | 5 | $91 |
| Kaleo, Inc. | 3 | $68 |
| Novartis | 4 | $61 |
| Hikma Pharmaceuticals USA | 3 | $54 |
| Integra Lifesciences Corporation | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Incyte Corporation | 3 | $40 |
| Polynovo North America LLC | 1 | $38 |
| Kerecis Limited | 1 | $34 |
| Phadia US Inc. | 2 | $32 |
| AbbVie | 1 | $25 |
| Lilly USA, LLC | 1 | $19 |
| LEO Pharma Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Intersect ENT, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
$2,398 in reported general payments places this provider in the 65th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 19 | $65,245 |
| Dupixent SyringeDupilumab | 11 | $63,783 |
| Ipratropium Bromide | 293 | $5,694 |
| Fluticasone Propionate | 355 | $5,140 |
| Azelastine Hcl | 161 | $3,487 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 24 | $2,888 |
| Fluocinolone Acetonide Oil | 29 | $2,722 |
| Prednisolone Acetate | 34 | $1,151 |
| Ofloxacin | 19 | $1,128 |
| Cefdinir | 50 | $972 |
| Montelukast Sodium | 91 | $935 |
| Levocetirizine Dihydrochloride | 59 | $758 |
| Famotidine | 88 | $662 |
| Omeprazole | 141 | $593 |
| Mupirocin | 57 | $363 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Islandia
- Robert KellmanSyracuse$2.5M
- Anthony DelsignoreNew York$966K
- Roheen RaithathaNew York$882K
- Dennis KrausNew York$524K
- Ashutosh KackerNew York$387K
- Lawrence LustigNew York$383K
- Brett MilesNew York$368K
- Alfred Marc IloretaNew York$342K
- Nora PerkinsAlbany$315K
- Gavin SetzenAlbany$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.